platinum has been researched along with Cancer of Head in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (11.39) | 18.7374 |
| 1990's | 11 (13.92) | 18.2507 |
| 2000's | 9 (11.39) | 29.6817 |
| 2010's | 20 (25.32) | 24.3611 |
| 2020's | 30 (37.97) | 2.80 |
| Authors | Studies |
|---|---|
| Bossi, P; Capriotti, V; Ghidini, A; Lorini, L; Luciani, A; Petrelli, F; Trevisan, F | 1 |
| Blumenschein, G; Colevas, AD; Even, C; Fayette, J; Ferris, RL; Gillison, ML; Guigay, J; Haddad, R; Harrington, KJ; Iglesias Docampo, LC; Jayaprakash, V; Kasper, S; Kiyota, N; Licitra, L; Rordorf, T; Saba, NF; Tahara, M; Vokes, EE; Wei, L; Worden, F | 1 |
| Guo, Y; Liu, Y; Xia, Z; Xue, L; Zhang, Q | 1 |
| Fushimi, C; Hanyu, K; Ito, T; Kondo, T; Masubuchi, T; Matsuki, T; Miura, K; Okada, T; Okamoto, I; Omura, GO; Oridate, N; Sato, H; Tada, Y; Takahashi, H; Tokashiki, K; Tsukahara, K; Yamashita, T | 1 |
| Ho, AL | 1 |
| Bossi, P; Caldara, A; Canevari, S; Caponigro, F; Carenzo, A; Cavalieri, S; De Cecco, L; Denaro, N; Ferrari, D; Ferraù, F; Lenoci, D; Licitra, L; Miceli, R; Moretti, G; Moro, C; Pistore, F; Rinaldi, G; Rocca, MC; Secondino, S; Serafini, MS; Sponghini, A; Vaccher, E; Vecchio, S | 1 |
| Fujii, T; Fujimoto, Y; Gumuscu, B; Hanai, N; Hara, H; Matsumoto, K; Mitsugi, K; Nakayama, M; Nohata, N; Oridate, N; Shiga, K; Shimizu, Y; Swaby, RF; Tahara, M; Takahashi, K; Takahashi, M; Takahashi, S; Tanaka, K; Ueda, T; Yamaguchi, H; Yamazaki, T; Yasumatsu, R; Yokota, T; Yoshizaki, T | 1 |
| Chang, KM; Hung, CJ; Kang, BH; Kang, YY; Lee, CC; Yin, CH | 1 |
| Chang, JT; Chou, WC; Hsu, CC; Hsueh, SW; Hung, CY; Lin, YC; Lu, CH; Su, PH; Wang, HM; Yeh, KY | 1 |
| Biancalana, L; Ermini, ML; Frusca, V; Giannini, N; Gonnelli, A; Mapanao, AK; Marchetti, F; Santi, M; Sarogni, P; Voliani, V; Zamborlin, A | 1 |
| Biswas, S; Ghosh, B; Itoo, AM; Paul, M | 1 |
| Cabezas-Camarero, S; Cabrera-Martín, MN; Cerezo Druet, E; Iglesias-Moreno, MC; Merino-Menéndez, S; Pérez-Segura, P; Plaza-Hernández, JC; Sotelo, MJ | 1 |
| Campbell, SR; Geiger, JL; Koyfman, S; Lopetegui-Lia, N; Roof, L; Schwartzman, LM; Silver, N; Woody, NM; Yalamanchali, A; Yang, K; Yilmaz, E | 1 |
| Acharya, R; Anderson, JL; Delgoffe, GM; Ferris, RL; Harris, AL; Hsieh, RW; Li, J; Menk, AV; Nilsen, ML; Scheff, NN; Swartz, A; Zandberg, DP | 1 |
| Argiris, A; Bratland, Å; Chung, CH; Coutte, A; de Azevedo, S; Even, C; Fayette, J; Ferris, RL; Gillison, M; Grant, C; Grell, P; Haddad, R; Hansen, AR; Harrington, KJ; Khan, TA; Miller-Moslin, K; Redman, R; Roberts, M; Salas, S; Schenker, M; Soulières, D; Tahara, M; Walker, JWT; Wei, L | 1 |
| Bonomo, P; Borcoman, E; Cau, MC; Depenni, R; Ghi, MG; Ghiani, M; Le Tourneau, C; Leo, L; Messinger, D; Montesarchio, V; Ronzino, G; Salmio, S; Sbrana, A; Schulten, J | 1 |
| Badulescu, F; Mirestean, CC; Stan, MC | 1 |
| Borel, C; Chevalier, T; Collet, L; Daste, A; Fayette, J; Huguet, F; Richard, S; Saada-Bouzid, E; Salas, S; Tardy, M; Vienne, A | 1 |
| Ito, T; Okada, T; Okamoto, I; Tokashiki, K; Tsukahara, K; Yamashita, G | 1 |
| Ahn, MJ; Burtness, B; Cohen, EEW; Dinis, J; Ge, J; Harrington, KJ; Lerman, N; Licitra, L; Lin, J; Mach, N; Machiels, JP; Mehra, R; Soria, A; Soulières, D; Swaby, RF; Tourneau, CL | 1 |
| Chang, PM; Chen, HL; Hsin, CH; Huang, WS; Lu, HJ; Peng, CY; Tseng, HC; Tseng, SW; Wu, MF; Yang, MH | 1 |
| Casak, S; Cheng, J; Donoghue, M; Fashoyin-Aje, L; Goldberg, KB; Jiang, X; Khazraee, M; Lemery, S; Liu, J; Mushti, S; Pazdur, R; Pelosof, L; Saung, MT; Theoret, M; Zhao, H | 1 |
| Ding, H; Fang, Q; Tong, Y; Xin, W; Xu, G; Yang, G; Zheng, X | 1 |
| Fang, J; Feng, L; He, S; Lian, M; Ma, H; Tan, C; Wang, L; Wang, R; Yang, Y | 1 |
| Hwang, M; Seiwert, TY | 1 |
| Shi, YF; Xie, WZ | 1 |
| Abakumov, MA; Abdul Razak, IB; Aisa, HA; Akhmirov, RT; Aladinskaya, AV; Allem, JP; Allu, SR; Ambale-Venkatesh, B; Anasori, B; Arizcorreta, A; Armentrout, PB; Baumann, H; Beloglazkina, EK; Ben-Elyiahu, Y; Ber, AP; Berthon, C; Bettelheim, A; Bluemke, DA; Bonsignore, M; Bordet, A; Borruso, A; Boxer, MB; Bress, AP; Brimacombe, KR; Brown, DE; Brüggemann, M; Cafeo, A; Cao, K; Cao, L; Carnicelli, J; Carr, JC; Cavallo, L; Cazin, CSJ; Cheff, DM; Chen, G; Chen, H; Chen, J; Chen, R; Chen-Sankey, JC; Cheng, C; Cheng, Y; Cheruku, RR; Chida, N; Choi, K; Chu, M; Cipolli, M; Colantonio, LD; Collado, A; Cook, J; Cordes, DB; Covey, J; Cuesta-Sancho, S; Davis, MI; Demireva, M; Derington, CG; Di Rosa, G; Dicanio, D; Dong, G; Dontsova, OA; Dormanesh, A; Dovrat, G; Duan, XM; Duarte, DA; Efthymiou, S; Erofeev, AS; Falivene, L; Fang, Y; Feng, D; Fernandes, VRS; Finko, AV; Freitag, TM; Frye, S; Gachot, C; Gao, S; Garanina, AS; Getya, D; Girón-González, JA; Girón-Ortega, JA; Gitsov, I; Gorelkin, PV; Grützmacher, PG; Guo, PY; Gutiérrez-Saborido, D; Habibi, M; Hall, MD; Hayes-Ryan, D; He, ZZ; Henderson, MJ; Herrick, JS; Herrmann, H; Hoang, Y; Hofmann, W; Hollingshead, M; Houlden, H; Hu, L; Huang, B; Huang, Y; Hussain, M; Huynh, HP; Iansa, P; Ivanenkov, YA; Jadhav, A; Jalaludin, B; Jalava, P; Karavadhi, S; Karpasas, M; Katahara, S; Kawel-Boehm, N; Khazanova, ES; King, JB; Klumpp-Thomas, C; Knibbs, LD; Komiya, Y; Komppula, M; Kranidiotis-Hisatomi, N; Krasnovskaya, OO; Kwiezinski, C; Lee, SW; Lee, TD; Leitner, W; Lerner, A; Leskinen, A; Li, B; Li, J; Li, Y; Li, Z; Liang, D; Liao, HB; Lima, JAC; Lin, L; Lin, W; Lin, Z; Liu, H; Liu, K; Liu, L; Liu, Q; Liu, Y; Lu, K; Luo, M; Ma, B; Machulkin, AE; Maimon, E; Majouga, AG; Márquez-Coello, M; Martinez, NJ; McCarthy, C; McIver, A; Meaney, S; Melotti, P; Menin, L; Mertes, S; Michael, S; Missert, JR; Moisy, P; Monda, KL; Mondello, P; Moore, WJ; Mücklich, F; Mues, KE; Muntner, P; Nahra, F; Navar, AM; Nelson, DJ; Nelson, RE; Ni, S; Nicotera, AG; Nimenko, EA; Nolan, SP; O'Donoghue, K; Oestreich, M; Pandey, RK; Pang, RD; Patnaik, S; Pei, W; Petrov, SA; Pevzner, S; Phillips, KS; Pintani, E; Pironti, E; Pokrovsky, VS; Polshakov, VI; Poudel, B; Pragani, R; Presser, V; Qu, H; Rahsepar, AA; Ramsey, MW; Ravotto, L; Ren, D; Ren, G; Ren, L; Rogach, AL; Rohde, JM; Roponen, M; Rosen, BD; Rosenkranz, A; Rosenson, RS; Salpietro, V; Saltykova, IV; Sato, T; Saveliev, OY; Senger, AR; Shafikov, RR; Shataer, D; Shen, M; Shi, Y; Shu, X; Simeonov, A; Skvortsov, DA; Slawin, AMZ; Smirnova, GB; Song, G; Stevens, VW; Stott, GM; Stratmann, F; Su, BJ; Suarez, S; Sugiyama, Y; Tabaczynski, W; Teo, KL; Tolosa, A; Totorika, A; Tracy, EC; Treggiari, D; Tridello, G; Troxler, T; Urban, DJ; Uspenskaya, AA; Vainer, R; Van Hecke, K; van Pinxteren, D; Vanden Broeck, SMP; Vanneman, ME; Vinogradov, SA; Wang, B; Wang, H; Wang, HS; Wang, L; Wang, R; Wang, X; Wang, YQ; Weller, C; Winkler-Heil, R; Xia, F; Xiao, F; Xin, XL; Xing, H; Xu, J; Xu, SL; Xu, Z; Yamane, M; Yamansarov, EU; Yan, T; Yang, BY; Yang, G; Yang, L; Yang, P; Yang, X; Yao, T; Yasgar, A; Ye, N; Yi, H; Yin, C; Yu, DYW; Yu, HY; Yu, J; Yuan, M; Zagefka, H; Zeng, XW; Zhang, H; Zhang, S; Zhang, W; Zhao, D; Zhao, W; Zhao, X; Zheng, H; Zheng, YK; Zhu, X; Zilbermann, I; Zyk, NU; Zyk, NV | 1 |
| Dai, T; Liu, S; Lv, S; Pei, R; Shi, Y; Wu, B; Zhang, F | 1 |
| Maslov, DV; Matrana, M; Thomas, K | 1 |
| Fang, J; Wang, L; Wang, R | 1 |
| Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E | 1 |
| Tahara, M | 1 |
| Strohbehn, GW; Vokes, EE | 1 |
| Braakhuis, BJ; Brakenhoff, RH; Brink, A; Dalm, SU; Honeywell, RJ; Martens-de Kemp, SR; Peters, GJ; Wijnolts, FM | 1 |
| Chan, C; Colevas, AD; Jiang, W; Kong, C; Le, QT; Lee-Enriquez, N; Murphy, JD; Pinto, H; Tang, C; von Eyben, R | 1 |
| Alves, MP; Avezedo, I; de Mello, RA; Dinis, J; Gerós, S; Moreira, F | 1 |
| Cohen, EE; Haddad, RI; Licitra, LF; Machiels, JP; Tahara, M | 1 |
| Fukuda, S; Furusawa, J; Hatakeyama, H; Homma, A; Iizuka, S; Kano, S; Mizumachi, T; Onimaru, R; Sakashita, T; Shirato, H; Tsuchiya, K; Yasuda, K | 1 |
| Caponigro, F; Clement, PM; Cohen, EE; Cong, XJ; Cupissol, D; de Castro, G; de Souza Viana, L; Del Campo, JM; Ehrnrooth, E; Fayette, J; Gauler, T; Grau, JJ; Guigay, J; Haddad, RI; Keilholz, U; Licitra, LF; Machiels, JP; Tahara, M; Vermorken, JB | 2 |
| Blumenschein, GR; Canales, JR; Ginsberg, LE; Heymach, JV; Kies, MS; Lee, JJ; Lin, H; Lu, C; Massarelli, E; Papadimitrakopoulou, V; Tran, HT; Williams, MD | 1 |
| Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D | 1 |
| Cabral, H; Kataoka, K; Makino, J; Miura, Y; Miyano, K; Mochida, Y; Nagano, O; Nishiyama, N; Saya, H; Tanabe, A; Tsuchihashi, K; Wang, M; Yoshikawa, M | 1 |
| Binder, M; Bokemeyer, C; Braig, F; Busch, CJ; Grob, T; Knecht, R; Kriegs, M; Laban, S; Schieferdecker, A; Voigtlaender, M | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Jeremić, B; Milicić, B | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Ciuleanu, T; Darstein, CL; Latz, JE; Musib, LC; Specenier, PM; Vermorken, JB | 1 |
| Azari, AA; Bhirde, AA; Gutkind, JS; Leapman, RD; Patel, V; Rusling, JF; Sousa, AA | 1 |
| Benasso, M; Erfán, J; Hitt, R; Kawecki, A; Licitra, L; Mesia, R; Remenár, É; Rivera, F; Rottey, S; Senger, S; Störkel, S; Stroh, C; Vermorken, JB; Zabolotnyy, D | 1 |
| Chen, P; Cohen, EE; Cox, NJ; Das, S; Delaney, S; Dolan, ME; Gamazon, ER; Huang, RS; Im, HK; O'Donnell, PH; Shukla, S; Vokes, EE; Ziliak, D | 1 |
| Burhenne, J; Detering, JC; Dyckhoff, G; Haefeli, WE; Herold-Mende, C; Theile, D; Weiss, J | 1 |
| Cao, JQ; Hannouf, MB; Mocanu, JD; Sehgal, C; Winquist, E; Zaric, GS | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| Balosso, J; Biston, MC; Bohic, S; Bravin, A; Brochard, T; Charvet, AM; Corde, S; Ducros, V; Elleaume, H; Estève, F; Fiedler, S; Joubert, A; Le Bas, JF; Nemoz, C; Renier, M; Simionovici, A; Thomlinson, W; Troprès, I | 1 |
| Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
| Glick, JH; Marcial, V; Richter, M; Velez-Garcia, E | 1 |
| Kuhn, JG; Mattox, DE; Repta, AJ; Sternson, LA; Von Hoff, DD | 1 |
| Fujii, M; Horiuchi, M; Inuyama, Y; Kohno, N; Mashino, S | 1 |
| Jacobs, C; Kalman, SM; Tretton, M; Weiner, MW | 1 |
| Henkel, H; Nagel, GA; von Heyden, HW; Weinstock, N | 1 |
| Barton, R; Blommaert, fA; den Engelse, L; Hanchett, C; Heath, DD; Howell, SB; Los, G; Robbins, KT; Vicario, D; Weisman, R | 1 |
| Allain, P; Delva, R; Gamelin, E; Larra, F; Lortholary, A; Maillart, P; Turcant, A | 1 |
| al-Sadhan, FA; Ali, PA; Dutton, J; el-Sharkawi, AM; Evans, CJ; Hancock, DA; Lewis, DG | 1 |
| Baan, RA; Braakhuis, BJ; Cloos, J; Fichtinger-Schepman, AM; Hermsen, MA; van der Vijgh, WJ; Welters, MJ | 1 |
| Al-Hussany, AF; Ali, PA; Bennett, CA; El-Sharkawi, AM; Hancock, DA | 1 |
| Bennett, CA; Kilic, A; Lewis, DG; Szalóki, I | 1 |
| Braakhuis, BJ; Cloos, J; Fichtinger-Schepman, AM; Pankras, JE; Smeets, SJ; Welters, MJ | 1 |
| Andrews, PA; Cullen, KJ; Ellison, CD; Faustino, PJ; Monastra, R; Rasmussen, AA; Yang, Z | 1 |
| Al-Ghorabie, FH; Al-Lyhiani, SH; Natto, SS | 1 |
| Balcerzak, S; Bender, J; Brooks, R; Chan, KK; D'Ambrosio, S; Gibson-D'Ambrosio, R; Grever, M; Kraut, E; Liu, J; Stanley, H | 1 |
| Holding, JD; Lindup, WE; Schilling, V; Stell, PM; van Laer, C; Vreeburg, GC; Wilson, JA | 1 |
| Egorin, MJ; Haraf, DJ; Mick, R; Moormeier, JA; Ratain, MJ; Vokes, EE; Weichselbaum, RR | 1 |
| Bowdler, DA; Holding, JD; Lindup, WE; Siodlak, MZ; Stell, PM | 1 |
| Börjesson, J; Jonson, R; Mattsson, S; Unsgaard, B; Wallgren, A | 1 |
| Atkinson, N; Castellanos, AM; Choksi, AJ; Dimery, IW; Felder, TB; Hong, WK; McCarthy, K; Newman, RA; Paredes, J; Robbins, KT | 1 |
| Adenis, L; Caty, A; Fournier, C; Hecquet, B; Lefebvre, JL | 1 |
| Apchin, A; Foka, M; Gouyette, A; Richard, JM | 1 |
| Adenis, L; Bonneterre, J; Caty, A; Demaille, A; Fournier, C; Hecquet, B; Lefebvre, JL; Vennin, P | 1 |
3 review(s) available for platinum and Cancer of Head
| Article | Year |
|---|---|
Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Network Meta-Analysis; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Aged; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Nivolumab; Platinum; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Registries; Squamous Cell Carcinoma of Head and Neck; United States | 2021 |
19 trial(s) available for platinum and Cancer of Head
| Article | Year |
|---|---|
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms; Humans; Japan; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Humans; Nivolumab; Platinum | 2021 |
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Protocols; Disease Progression; Head and Neck Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Retreatment; Squamous Cell Carcinoma of Head and Neck | 2014 |
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemistry, Pharmaceutical; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2016 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2016 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
Pretreatment prognostic factors of local recurrence-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy.
Topics: Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Platinum; Prognosis; Radiation Dosage | 2008 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cisplatin; Cross-Over Studies; Dietary Supplements; Female; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Treatment Outcome | 2009 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Fluorouracil; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; DNA Adducts; Dose-Response Relationship, Drug; Drug Interactions; Head and Neck Neoplasms; Humans; Leukocytes; Mass Spectrometry; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Reproducibility of Results | 2002 |
Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Compounding; Drug Evaluation; Head and Neck Neoplasms; Humans; Platinum; Serum Albumin | 1992 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Leucovorin; Lung Neoplasms; Male; Middle Aged; Platinum | 1992 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Ditiocarb; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kidney; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Random Allocation | 1988 |
Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Topics: Adult; Antineoplastic Agents; Carboplatin; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Organoplatinum Compounds; Platinum | 1987 |
57 other study(ies) available for platinum and Cancer of Head
| Article | Year |
|---|---|
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2022 |
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2022 |
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Head and Neck Neoplasms; Humans; Inflammation; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy.
Topics: Alanine Transaminase; Body Composition; Docetaxel; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Platinum; Retrospective Studies | 2022 |
Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Topics: Chemoradiotherapy; Head and Neck Neoplasms; Humans; Patient Compliance; Platinum; Prospective Studies | 2022 |
Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas.
Topics: Carcinoma, Squamous Cell; Cisplatin; Coordination Complexes; Head and Neck Neoplasms; Humans; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Hypoxia alleviating platinum(IV)/chlorin e6-based combination chemotherapeutic-photodynamic nanomedicine for oropharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorophyllides; Head and Neck Neoplasms; Hypoxia; Mice; Mouth Neoplasms; Nanomedicine; Nanoparticles; Oxygen; Photochemotherapy; Photosensitizing Agents; Platinum; Porphyrins; Squamous Cell Carcinoma of Head and Neck | 2023 |
Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Topics: Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Comparison of real-world outcomes following immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma with outcomes of randomized controlled trials.
Topics: Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Recurrence, Local; Platinum; Randomized Controlled Trials as Topic; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Analgesics, Opioid; Antibodies, Monoclonal; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Female; Head and Neck Neoplasms; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment | 2023 |
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Topics: Carcinoma, Squamous Cell; Double-Blind Method; Head and Neck Neoplasms; Humans; Immunotherapy; Ipilimumab; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Implications of diabetes in head and neck cancer - A single center real-world data.
Topics: Diabetes Mellitus; Head and Neck Neoplasms; Humans; Metformin; Platinum; Prognosis | 2023 |
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |
Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Topics: Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Nivolumab; Platinum; Squamous Cell Carcinoma of Head and Neck | 2023 |
Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease Progression; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis | 2021 |
Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Topics: Antibodies, Monoclonal, Humanized; China; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Quality-Adjusted Life Years; Squamous Cell Carcinoma of Head and Neck | 2020 |
A novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy.
Topics: Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Platinum; Taxoids | 2021 |
A novel seven‑gene panel predicts prognosis of head and neck squamous cell carcinoma treated with platinum‑based radio(chemo)therapy.
Topics: Chemoradiotherapy; Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antigens, Surface; Antineoplastic Agents; Antioxidants; Antiviral Agents; Aporphines; Atherosclerosis; Benzoyl Peroxide; beta Catenin; Biofilms; Biomarkers; Brain; Cannabis; Carcinoma, Squamous Cell; Case-Control Studies; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Child; China; Chlorides; Chlorophyll; Cholesterol, LDL; Coinfection; Corylus; Cross-Sectional Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Developmental Disabilities; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Electroencephalography; Environmental Exposure; Enzyme Inhibitors; Epilepsy, Generalized; Ethnicity; Female; Fertilization in Vitro; Fluorescent Dyes; Follow-Up Studies; Forecasting; Glutamate Carboxypeptidase II; Glycine; Half-Life; Head and Neck Neoplasms; Health Communication; Heart Ventricles; Hepacivirus; Hepatitis C; Heterosexuality; HIV Infections; Humans; Hypercholesterolemia; Immunoassay; Inhalation Exposure; Isocitrate Dehydrogenase; Laryngeal Neoplasms; Ligands; Light; Lipopolysaccharide Receptors; Liver Cirrhosis; Lung; Lung Neoplasms; Magnetic Resonance Imaging, Cine; Male; Maternal Age; Mechanical Phenomena; Mice; Mice, Nude; Mice, SCID; Microglia; MicroRNAs; Microscopy, Fluorescence; Microsomes, Liver; Middle Aged; Minority Groups; Mitochondrial Membrane Transport Proteins; Models, Biological; Molecular Structure; Molecular Weight; Monte Carlo Method; Muscle Hypotonia; Mutagenesis, Site-Directed; Mutation, Missense; Natriuretic Peptide, Brain; Neoplasms; Nickel; Nitric Oxide; Optical Imaging; Oxides; Particle Size; Particulate Matter; PCSK9 Inhibitors; Peptide Fragments; Phenotype; Photochemotherapy; Photosensitizing Agents; Phytochemicals; Piper; Placenta Growth Factor; Plant Extracts; Plant Leaves; Plant Stems; Platinum; Point-of-Care Testing; Population Surveillance; Postpartum Period; Pregnancy; Pregnancy, Twin; Prevalence; Prospective Studies; Prostatic Neoplasms; Pseudomonas aeruginosa; Pyridines; Pyridones; Racial Groups; Rats; Respiratory Physiological Phenomena; Retrospective Studies; Risk Factors; RNA, Long Noncoding; Semiconductors; Sexual and Gender Minorities; Sexual Behavior; Social Media; Sodium; Solubility; Stereoisomerism; Stochastic Processes; Structure-Activity Relationship; Substance-Related Disorders; Sustained Virologic Response; Sweat; Temperature; Time Factors; Tissue Distribution; Titanium; Transplantation, Heterologous; Tumor Cells, Cultured; Tungsten; Tyramine; United States; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Function, Left; Veterans; Xenograft Model Antitumor Assays; Young Adult | 2021 |
Utilization of Nivolumab in Adenoid Cystic Carcinoma After Progression on Platinum-Based Chemotherapy.
Topics: Carcinoma, Adenoid Cystic; Head and Neck Neoplasms; Humans; Male; Nivolumab; Platinum; Tomography, X-Ray Computed; Young Adult | 2021 |
Author's reply to "A novel seven-gene panel predicts the sensitivity and prognosis of head and neck squamous cell carcinoma treated with platinum-based radio(chemo)therapy".
Topics: Head and Neck Neoplasms; Humans; Platinum; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2021 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Practice Patterns, Physicians'; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
[The Concept of Platinum-Resistance and Treatment Strategies in Head and Neck Cancer].
Topics: Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Platinum | 2019 |
Palbociclib: a new partner for cetuximab?
Topics: Cetuximab; Head and Neck Neoplasms; Humans; Papillomaviridae; Papillomavirus Infections; Piperazines; Platinum; Pyridines | 2019 |
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mutation; Platinum; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Tumor Suppressor Protein p53 | 2013 |
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Risk Assessment; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2015 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Europe; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Grading; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Female; Head and Neck Neoplasms; Humans; Incidence; Japan; Male; Middle Aged; Mucositis; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck | 2015 |
Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines.
Topics: Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; DNA; Drug Carriers; Female; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Mice, Inbred BALB C; Micelles; Nanomedicine; Platinum | 2016 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Fluorouracil; GTP Phosphohydrolases; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Membrane Proteins; Mutation; Platinum; Proto-Oncogene Proteins p21(ras); ras Proteins | 2016 |
Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes.
Topics: Antineoplastic Agents; Cell Line, Tumor; Head and Neck Neoplasms; Humans; Microscopy, Electron, Scanning Transmission; Models, Biological; Nanomedicine; Nanotubes, Carbon; Platinum; Spectrometry, X-Ray Emission; Spectroscopy, Fourier Transform Infrared | 2009 |
Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers.
Topics: Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Models, Biological; Platinum; Polymorphism, Genetic; Treatment Outcome | 2011 |
Cellular pharmacokinetic/pharmacodynamic relationship of platinum cytostatics in head and neck squamous cell carcinoma evaluated by liquid chromatography coupled to tandem mass spectrometry.
Topics: Aged; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, Liquid; Cytostatic Agents; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Platinum; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Tandem Mass Spectrometry | 2012 |
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cost-Benefit Analysis; Head and Neck Neoplasms; Humans; Models, Theoretical; Platinum | 2012 |
Lack of cell death enhancement after irradiation with monochromatic synchrotron X rays at the K-shell edge of platinum incorporated in living SQ20B human cells as cis-diamminedichloroplatinum (II).
Topics: Calibration; Cell Cycle; Cell Death; Cell Line; Cell Survival; Cisplatin; Colony-Forming Units Assay; Dose-Response Relationship, Radiation; Flow Cytometry; Head and Neck Neoplasms; Humans; Particle Accelerators; Photons; Platinum; Radiation-Sensitizing Agents; Tumor Cells, Cultured; X-Rays | 2002 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
The adjuvant treatment of inoperable stage III and IV epidermoid carcinoma of the head and neck with platinum and bleomycin infusions prior to definitive radiotherapy: an RTOG pilot study.
Topics: Anemia; Bleomycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Male; Middle Aged; Nausea; Pilot Projects; Platinum; Uremia; Vomiting | 1980 |
Tumor concentration of platinum in patients with head and neck cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cisplatin; Dogs; Dose-Response Relationship, Drug; Drug Resistance; Head and Neck Neoplasms; Humans; In Vitro Techniques; Platinum | 1983 |
[Pharmacokinetics of cis-dichlorodiammineplatinum (II)].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cisplatin; Head and Neck Neoplasms; Humans; Kinetics; Platinum; Spectrophotometry, Atomic | 1982 |
Renal handling of cis-diamminedichloroplatinum(II).
Topics: Cisplatin; Creatinine; Female; Glomerular Filtration Rate; Head and Neck Neoplasms; Humans; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Platinum; Time Factors | 1980 |
[Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].
Topics: Adult; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Kinetics; Lung Neoplasms; Lymphoma; Male; Middle Aged; Ovarian Neoplasms; Platinum; Testicular Neoplasms | 1982 |
Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.
Topics: Antineoplastic Agents; Cisplatin; Combined Modality Therapy; DNA Adducts; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Platinum | 1995 |
Long-term pharmacokinetic behavior of platinum after cisplatin administration.
Topics: Aged; Antineoplastic Agents; Cisplatin; Head and Neck Neoplasms; Humans; Middle Aged; Platinum; Ultracentrifugation | 1995 |
Initial measurements of platinum concentration in head and neck tumors using X-ray fluorescence.
Topics: Body Composition; Carboplatin; Cisplatin; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Platinum; Spectrometry, X-Ray Emission; Technetium | 1993 |
Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Cell Line; Cisplatin; DNA, Neoplasm; Female; Head and Neck Neoplasms; Humans; Kinetics; Male; Middle Aged; Platinum; Time Factors; Tumor Cells, Cultured | 1997 |
Plane polarized x-ray fluorescence system for the in vivo measurement of platinum in head and neck tumours.
Topics: Cisplatin; Equipment Design; Head and Neck Neoplasms; Humans; Platinum; Radiography; Sensitivity and Specificity; Spectrometry, X-Ray Emission | 1998 |
Application of the fundamental parameter method to the in vivo x-ray fluorescence analysis of Pt.
Topics: Biophysical Phenomena; Biophysics; Head and Neck Neoplasms; Humans; Phantoms, Imaging; Platinum; Scattering, Radiation; Spectrometry, X-Ray Emission; Technetium | 1999 |
Effect of cisplatin exposure on platinum accumulation and growth inhibition in human neoplastic and normal squamous epithelial cells of the mucosa of the upper-aerodigestive tract.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Epithelial Cells; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Platinum; Tumor Cells, Cultured; Uvula | 1999 |
Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cisplatin; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Glutathione; Head and Neck Neoplasms; Humans; Neoplasms, Squamous Cell; Platinum; Spectrophotometry, Atomic; Tumor Cells, Cultured | 2000 |
A comparison between EGS4 and MCNP computer modeling of an in vivo X-ray fluorescence system.
Topics: Computer Simulation; Head and Neck Neoplasms; Humans; Mathematical Computing; Monte Carlo Method; Phantoms, Imaging; Platinum; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, X-Ray Emission; Xenon Radioisotopes | 2001 |
Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.
Topics: Adult; Aged; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Platinum; Serum Albumin | 1991 |
Uptake and retention of platinum in patients undergoing cisplatin therapy.
Topics: Adolescent; Adult; Aged; Brain; Brain Neoplasms; Cisplatin; Head and Neck Neoplasms; Humans; Kidney; Male; Middle Aged; Platinum; Spectrometry, X-Ray Emission; Testicular Neoplasms | 1991 |
Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.
Topics: Adult; Cisplatin; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Infusions, Parenteral; Kinetics; Male; Middle Aged; Platinum | 1986 |
Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.
Topics: Breast Neoplasms; Cisplatin; Female; Head and Neck Neoplasms; Humans; Kinetics; Platinum; Uterine Cervical Neoplasms | 1985 |